Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.38 |
| ▸ | LPL | P06858 | 6/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | F11 | P03951 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29607986 | 0.90 | HIF1A (0.36) | LIPGLPLHIF1AP4HBCA1 | |
| SCHEMBL30032727 | 0.87 | ALDH1A1 (0.41) | LIPGLPLHIF1AP4HBCA1 | |
| SCHEMBL29897650 | 0.85 | HSP90AA1 (0.43) | LIPGLPLHIF1AP4HBCA1 | |
| SCHEMBL14513575 | 0.84 | LIPG (0.42) | LIPGLPLHIF1AP4HBCA1 | |
| SCHEMBL12069299 | 0.84 | ROCK1 (0.46) | LIPGLPLHIF1AP4HBCA1 | |
| SCHEMBL22858943 | 0.84 | HIF1A (0.36) | LIPGLPLHIF1AP4HBCA1 | |
| SCHEMBL2802162 | 0.84 | HIF1A (0.36) | LIPGLPLHIF1AP4HBCA1 | |
| SCHEMBL21682776 | 0.83 | CA1 (0.42) | LIPGLPLHIF1AP4HBCA1 | |
| SCHEMBL458415 | 0.83 | LIPG (0.45) | LIPGLPLHIF1AP4HBCA1 | |
| SCHEMBL3491328 | 0.83 | F11 (0.40) | LIPGLPLHIF1AP4HBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010936-A | Multi-kinase inhibitor, PROTACs target protein ligand, and synthesis method and application thereof | 杭州医学院 | 2026-05-12 | — | — | CN | disclosed |
| US-20260042754-A1 | Substituted Bicyclic Heteroaryl Sulfonamide Derivatives for the Treatment of Cancer | NODUS ONCOLOGY LIMITED (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12459958-B2 | Tricyclic compounds as HPK1 inhibitor and the use thereof | BEONE MEDICINES I GMBH (CH) | 2025-11-04 | — | — | US | disclosed |
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | BEONE MEDICINES I GMBH (CH) | 2025-10-28 | — | — | US | disclosed |
| EP-4562002-A1 | SUBSTITUTED BICYCLIC HETEROARYL SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | Nodus Oncology Limited (GB) | 2025-06-04 | — | — | EP | disclosed |
| US-20240228497-A1 | Pyrrolo[2, 3-b]Pyrazine-Based Bifunctional Compounds as HPK1 Degraders and the Use Thereof | BEIGENE, LTD. (KY) | 2024-07-11 | — | — | US | disclosed |
| EP-4377318-A1 | PYRROLO [2, 3-B] PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND THE USE THEREOF | BeiGene, Ltd. (KY) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024023330-A1 | SUBSTITUTED BICYCLIC HETEROARYL SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | NODUS ONCOLOGY LIMITED (GB) | 2024-02-01 | — | — | WO | disclosed |
| CN-116731029-A | Parallel ring compound and preparation and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116199636-A | 2, 4-disubstituted pyrimidine derivative of targeted tumor immunity kinase, preparation method and application thereof | 杭州医学院 | 2023-06-02 | — | — | CN | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| EP-2155201-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | LIPG 4230/4885LPL 4859/4885HIF1A 2046/4885 |
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | PDXK, STK25, STK35 | LIPG 2878/4885LPL 1661/4885HIF1A 1707/4885 |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | BACE1, APP, PSEN1 | LIPG 3115/4885LPL 1662/4885HIF1A 3459/4885 |
| US-20260042754-A1 | Substituted Bicyclic Heteroaryl Sulfonamide Derivatives for the Treatment of Cancer | CBR1, CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | LIPG 3684/4885LPL 4277/4885HIF1A 1294/4885 |
| US-20240228497-A1 | Pyrrolo[2, 3-b]Pyrazine-Based Bifunctional Compounds as HPK1 Degraders and the Use Thereof | HIPK1, MDM2, JMJD7 | LIPG 3724/4885LPL 3606/4885HIF1A 1927/4885 |
| US-12459958-B2 | Tricyclic compounds as HPK1 inhibitor and the use thereof | ULK1, SBK1, PHKG1 | LIPG 2026/4885LPL 900/4885HIF1A 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.